Delcath Systems 경영진
경영진 기준 점검 3/4
Delcath Systems CEO는 Gerard Michel, Oct2020 에 임명되었습니다 의 임기는 5.58 년입니다. 총 연간 보상은 $5.77M, 11% 급여 및 89% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $3.92M 가치에 해당하는 회사 주식의 0.99% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 2.9 년과 6 년입니다.
핵심 정보
Gerard Michel
최고경영자
US$5.8m
총 보수
| CEO 급여 비율 | 11.03% |
| CEO 재임 기간 | 5.6yrs |
| CEO 지분 보유율 | 1.0% |
| 경영진 평균 재임 기간 | 2.9yrs |
| 이사회 평균 재임 기간 | 6yrs |
최근 경영진 업데이트
Recent updates
내러티브 업데이트 • Apr 30
DCTH: 2026 Spend Increase Will Drive Hepatic Cancer Therapy Adoption
Analysts have trimmed their blended price target on Delcath Systems by about $2 to align with recent Street research that lowered the target to $27, citing updated FY26 sales guidance of at least $100m and sharply higher planned R&D and SG&A spending to support HEPZATO commercial and label expansion efforts. Analyst Commentary Bullish Takeaways Bullish analysts view the revised US$27 price target as still reflecting upside potential relative to current trading levels, even after trimming expectations.내러티브 업데이트 • Apr 16
DCTH: 2026 Spend Increase Will Support Hepatic Cancer Therapy Expansion
Analysts trimmed their price target on Delcath Systems to $27 from $29, citing updated guidance for at least $100M in FY26 sales and a very large projected increase in R&D and SG&A spending to support the HEPZATO label and commercial expansion. Analyst Commentary Recent commentary focuses on how the updated FY26 sales outlook and higher operating spend could affect the risk and reward profile for Delcath Systems, especially around execution on HEPZATO and future label opportunities.
내러티브 업데이트 • Apr 02
DCTH: Higher 2026 Spending Will Support Liver Cancer Therapy Expansion
Analysts have trimmed their average price target on Delcath Systems by $2, citing recent FY25 results, updated FY26 sales guidance of at least $100M versus prior consensus of $111M, and expectations for higher R&D and SG&A spending to support HEPZATO growth and label expansion. Analyst Commentary Recent Street commentary on Delcath Systems centers on how near term spending and updated sales guidance could affect the risk and reward profile for shareholders.내러티브 업데이트 • Mar 18
DCTH: Higher 2026 Spending Will Support Cancer Therapy Cash Flows And Expansion
Narrative Update on Delcath Systems The analyst price target for Delcath Systems has been trimmed by $2 to $27, as analysts factor in the company's FY26 sales guidance of at least $100M, along with sharply higher planned R&D and SG&A spending to support HEPZATO and label expansion. Analyst Commentary Recent research updates on Delcath Systems highlight a mixed reaction to the company’s outlook, with particular attention on FY26 guidance and the spending required to support HEPZATO and label expansion.내러티브 업데이트 • Mar 04
DCTH: Higher 2026 Spending Will Support Future Revenue Expansion Potential
Narrative Update on Delcath Systems The analyst price target for Delcath Systems has been reduced by $3 to $27. Analysts point to updated FY26 sales guidance of at least $100M and significantly higher projected R&D and SG&A spending to support HEPZATO growth and label expansion as key factors behind the change.내러티브 업데이트 • Feb 18
DCTH: Steadier Cancer Therapy Cash Flows Will Support Future Indication Expansion
Analysts have raised their price target on Delcath Systems by $1 to $29, citing preliminary Q4 results that indicate Hepzato is becoming a more stable revenue contributor, with more predictable quarter-to-quarter trends and cash flow that may support expansion plans. Analyst Commentary Analysts highlighting the new US$29 price target point to Hepzato’s role as a steadier revenue source and to cash flow that may help support future expansion plans.내러티브 업데이트 • Feb 04
DCTH: Steadier Liver Cancer Therapy Revenues Will Support Future Indication Expansion
Analysts have nudged their price target on Delcath Systems higher to $29 from $28, pointing to Hepzato's role as a steady revenue contributor with more predictable quarter to quarter variability and cash flow that can support expansion of additional indications. Analyst Commentary Even with the higher price target, not all commentary around Delcath Systems leans positive.내러티브 업데이트 • Jan 20
DCTH: Steadier Hepatic Therapy Uptake Will Support Future Expansion Plans
Analysts recently lifted their price target on Delcath Systems to $29 from $28, citing Hepzato's role as a steadier and more predictable contributor to revenue and cash flow. They believe this supports potential expansion plans and informs modest adjustments to growth, margin, and future P/E assumptions.내러티브 업데이트 • Jan 06
DCTH: CHOPIN Trial Data Will Support Future Uptake Despite Softer Guidance
Analysts have kept their fair value estimate for Delcath Systems steady at $18.00 while adjusting underlying assumptions, citing mixed reactions to softer Q3 and FY2025 revenue guidance alongside supportive CHOPIN trial data and a range of updated price targets from $20 to $30. Analyst Commentary Street research on Delcath Systems has centered on the tension between supportive CHOPIN trial data and softer near term revenue guidance, with several price target revisions reflecting this mixed setup.내러티브 업데이트 • Dec 14
DCTH: CHOPIN Data Expected To Drive Stronger Uptake Despite Near-Term Guidance Reset
Analysts have trimmed their fair value estimate for Delcath Systems to $18.00 from $21.00, reflecting lower near term revenue growth assumptions after soft preliminary guidance. This comes despite sustained confidence in Hepzato uptake driven by positive CHOPIN trial data and improving profit margin expectations.분석 기사 • Nov 21
Why We're Not Concerned Yet About Delcath Systems, Inc.'s (NASDAQ:DCTH) 28% Share Price Plunge
The Delcath Systems, Inc. ( NASDAQ:DCTH ) share price has fared very poorly over the last month, falling by a...Seeking Alpha • Nov 06
Delcath: Temporary Headwinds Are No Cause For Concern
Summary Delcath's third quarter was weak due to seasonality and pricing headwinds, but data suggests these are temporary challenges. Delcath continues to expand its treatment sites and sales force, which should lead to strong growth in 2026. Clinical trials to expand the company's addressable market are also now under way, which could provide enormous upside in several years time. Delcath's valuation is extremely low given the prospect of continued growth and strong margins once growth investments normalize. Read the full article on Seeking Alpha분석 기사 • Oct 28
The Delcath Systems, Inc. (NASDAQ:DCTH) Analysts Have Been Trimming Their Sales Forecasts
The latest analyst coverage could presage a bad day for Delcath Systems, Inc. ( NASDAQ:DCTH ), with the analysts making...분석 기사 • Aug 09
Delcath Systems, Inc. Just Recorded A 200% EPS Beat: Here's What Analysts Are Forecasting Next
NasdaqCM:DCTH 1 Year Share Price vs Fair Value Explore Delcath Systems's Fair Values from the Community and select...분석 기사 • Jul 12
Why We're Not Concerned Yet About Delcath Systems, Inc.'s (NASDAQ:DCTH) 29% Share Price Plunge
Delcath Systems, Inc. ( NASDAQ:DCTH ) shares have retraced a considerable 29% in the last month, reversing a fair...분석 기사 • Jun 18
Delcath Systems (NASDAQ:DCTH) Is In A Strong Position To Grow Its Business
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...분석 기사 • May 22
Delcath Systems, Inc.'s (NASDAQ:DCTH) 52% Jump Shows Its Popularity With Investors
Delcath Systems, Inc. ( NASDAQ:DCTH ) shareholders would be excited to see that the share price has had a great month...분석 기사 • May 11
Delcath Systems, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
A week ago, Delcath Systems, Inc. ( NASDAQ:DCTH ) came out with a strong set of first-quarter numbers that could...
새로운 내러티브 • May 02
HEPZATO Launch And European Expansion Will Expand Treatment Access
Expansion in U.S. treatment centers and commercial teams is expected to drive significant revenue growth and improve operational efficiencies.분석 기사 • Mar 11
With A 27% Price Drop For Delcath Systems, Inc. (NASDAQ:DCTH) You'll Still Get What You Pay For
Delcath Systems, Inc. ( NASDAQ:DCTH ) shares have retraced a considerable 27% in the last month, reversing a fair...분석 기사 • Jan 18
Delcath Systems, Inc.'s (NASDAQ:DCTH) P/S Is Still On The Mark Following 31% Share Price Bounce
Delcath Systems, Inc. ( NASDAQ:DCTH ) shareholders have had their patience rewarded with a 31% share price jump in the...분석 기사 • Dec 19
Does Delcath Systems (NASDAQ:DCTH) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Seeking Alpha • Nov 18
Delcath Systems: Q3 Earnings Reveal HEPZATO KIT And CHEMOSAT Growth
Summary Delcath Systems' Q3 earnings revealed strong growth with $11.2M in revenue, driven by HEPZATO and CHEMOSAT sales, and an 85% gross margin. The company is expanding its commercial footprint with 12 active treatment centers and plans to reach 30 by the end of 2025. Promising growth drivers include new cancer indications for HEPZATO, potential label expansion, and combining with immune checkpoint inhibitors. Despite promising trends, investors should be cautious of seasonality impacts and the risks associated with upcoming Phase II trials and increased R&D expenses. I take a look at the charts to see if I can identify an opportunity to add to my position. Read the full article on Seeking Alpha분석 기사 • Nov 01
Delcath Systems, Inc.'s (NASDAQ:DCTH) P/S Is Still On The Mark Following 26% Share Price Bounce
Despite an already strong run, Delcath Systems, Inc. ( NASDAQ:DCTH ) shares have been powering on, with a gain of 26...분석 기사 • Sep 10
Delcath Systems, Inc.'s (NASDAQ:DCTH) 26% Jump Shows Its Popularity With Investors
Delcath Systems, Inc. ( NASDAQ:DCTH ) shares have continued their recent momentum with a 26% gain in the last month...분석 기사 • Aug 27
Is Delcath Systems (NASDAQ:DCTH) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...분석 기사 • Aug 07
Delcath Systems, Inc. (NASDAQ:DCTH) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Shareholders might have noticed that Delcath Systems, Inc. ( NASDAQ:DCTH ) filed its quarterly result this time last...분석 기사 • Jan 15
Is Delcath Systems (NASDAQ:DCTH) Using Debt In A Risky Way?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...CEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$561k |
| Dec 31 2025 | US$6m | US$636k | US$3m |
| Sep 30 2025 | n/a | n/a | US$1m |
| Jun 30 2025 | n/a | n/a | US$2m |
| Mar 31 2025 | n/a | n/a | -US$14m |
| Dec 31 2024 | US$2m | US$561k | -US$26m |
| Sep 30 2024 | n/a | n/a | -US$34m |
| Jun 30 2024 | n/a | n/a | -US$56m |
| Mar 31 2024 | n/a | n/a | -US$50m |
| Dec 31 2023 | US$3m | US$538k | -US$48m |
| Sep 30 2023 | n/a | n/a | -US$45m |
| Jun 30 2023 | n/a | n/a | -US$34m |
| Mar 31 2023 | n/a | n/a | -US$37m |
| Dec 31 2022 | US$1m | US$521k | -US$37m |
| Sep 30 2022 | n/a | n/a | -US$33m |
| Jun 30 2022 | n/a | n/a | -US$32m |
| Mar 31 2022 | n/a | n/a | -US$28m |
| Dec 31 2021 | US$2m | US$475k | -US$26m |
| Sep 30 2021 | n/a | n/a | -US$27m |
| Jun 30 2021 | n/a | n/a | -US$25m |
| Mar 31 2021 | n/a | n/a | -US$23m |
| Dec 31 2020 | US$6m | US$113k | -US$24m |
보상 대 시장: Gerard의 총 보수(USD5.77M)는 US 시장에서 비슷한 규모 기업의 평균(USD2.67M)보다 높습니다.
보상과 수익: Gerard의 보상은 지난 1년 동안 회사 실적과 일치했습니다.
CEO
Gerard Michel (62 yo)
5.6yrs
재임 기간
US$5,765,258
보수
Mr. Gerard J. Michel, MS, MBA, is an Independent Director of Beta Bionics, Inc. from March 26, 2025. Mr. Michel serves as Chief Executive Officer and Director at Delcath Systems Inc since October 1, 2020....
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| CEO & Director | 5.6yrs | US$5.77m | 0.99% $ 3.9m | |
| Chief Operating Officer | 2.2yrs | US$2.02m | 0.022% $ 87.8k | |
| Chief Medical Officer | 2.9yrs | US$2.06m | 0.49% $ 1.9m | |
| Chief Financial Officer | 2.9yrs | 데이터 없음 | 0.22% $ 881.9k | |
| General Counsel | 4.3yrs | 데이터 없음 | 0.25% $ 979.6k | |
| Senior Vice President of Clinical Operations & Medical Affairs | 5.3yrs | US$737.50k | 데이터 없음 | |
| Chief Commercial Officer | less than a year | US$1.02m | 0.071% $ 279.2k | |
| Senior Vice President of Interventional Oncology | 1.2yrs | 데이터 없음 | 데이터 없음 |
2.9yrs
평균 재임 기간
56.5yo
평균 나이
경험이 풍부한 관리: DCTH의 경영진은 경험이 있음으로 간주됩니다(평균 재임 2.9 년).
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| CEO & Director | 5.6yrs | US$5.77m | 0.99% $ 3.9m | |
| Independent Director | 6.3yrs | US$306.22k | 0% $ 0 | |
| Independent Director | 6yrs | US$306.22k | 0.24% $ 941.1k | |
| Independent Chairman | 6.8yrs | US$337.64k | 0.043% $ 171.0k | |
| Independent Director | 6yrs | US$293.72k | 0.15% $ 588.3k | |
| Director | 2yrs | US$301.22k | 0% $ 0 |
6.0yrs
평균 재임 기간
61yo
평균 나이
경험이 풍부한 이사회: DCTH의 이사회는 경험이 있음으로 간주됩니다(평균 재임 6 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/22 22:07 |
| 종가 | 2026/05/22 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Delcath Systems, Inc.는 12명의 분석가가 다루고 있습니다. 이 중 6명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Michael Gorman | BTIG |
| Marie Thibault | BTIG |
| John Newman | Canaccord Genuity |